A clinical trial of four potential Ebola treatments in Congo has been narrowed to focus on two of the experimental drugs - Regeneron's REGN-EB3 and a monoclonal antibody called mAb114 - after they showed encouraging results, scientists leading the trial said on Monday.
No comments:
Post a Comment